Archive | Clinical Trials

Adoptive T-Cell Therapy Induced Response in Metastatic Uveal Melanoma

More than one-third of patients with metastatic uveal melanoma had objective tumor regression when treated with adoptive transfer of autologous tumor-infiltrating lymphocytes (TILs), according to results of an unplanned interim analysis published recently in Lancet Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial

The combination of ImmunoPulse IL-12 and the anti-PD-1 therapy Keytruda (pembrolizumab) soon will be tested in a Phase 2 trial for treatment of metastatic melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Study points to melanoma breakthrough

Advanced melanoma patients with brain tumours may be able to live longer using a combination of immunotherapy drugs, an Australian trial has shown.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Data for KEYTRUDA® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2 – 6, 2017.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories